Latest Financial Position News

Genetic Signatures Ltd reports a robust start to FY2026 with a 20% quarterly sales increase, driven by new US contracts and strong growth in EMEA and Australia. The company also bolsters its leadership with a new CTO appointment.

Blue Star Helium Limited is poised to become a key U.S. helium and natural CO2 producer with first production from its Galactica project scheduled for December 2025. The company’s staged development plan and strategic joint venture position it to address growing domestic helium demand amid global supply constraints.

Wildcat Resources has identified viable processing methods for previously overlooked lithium and tantalum resources at its Tabba Tabba Project, potentially converting waste into valuable ore and enhancing project economics ahead of its Definitive Feasibility Study.

Yari Minerals has announced a substantial 140% increase in its JORC Inferred Coal Resource at the Rolleston South Project in Queensland, now totaling 190 million tonnes. The company is actively drilling to upgrade resource confidence and confirm coal quality, positioning itself for future development.

Advanced Braking Technology Ltd has kicked off FY26 with a 21% rise in product sales revenue and a 66% jump in net profit before tax, underpinned by expanding international demand and progress in autonomous braking systems.

Bubalus Resources has reported encouraging drilling results at its Victorian gold projects and is advancing rare earth exploration in the Northern Territory, supported by a solid cash position.

Talisman Mining’s recent drilling at Walkers Hill in NSW reveals promising shallow gold mineralisation, setting the stage for expanded exploration in the coming months. The company also reports solid royalty income and a healthy cash position.

Morella Corporation has locked in A$1.4 million in convertible note funding from key shareholders and directors, strengthening its financial position to advance critical minerals exploration and acquisitions.

Connected Minerals reports strong uranium grades from its Etango North-East Project in Namibia and progresses rare earth exploration plans in Western Australia, maintaining a solid financial footing.

Chalice Mining is progressing its Gonneville Project Pre-Feasibility Study on schedule for November 2025 completion, fully funded and targeting a Final Investment Decision by late 2027 as palladium prices hit a two-year high.

Radiopharm Theranostics has announced a $40 million equity raise via a two-tranche placement and a Share Purchase Plan (SPP) to fund its clinical programs and working capital. The offer includes new shares at $0.03 each with free attaching options, subject to shareholder approval.

Actinogen Medical has received approval for an additional $1.87 million research and development tax rebate, bringing its total FY25 rebate to $7.36 million. This funding underpins ongoing clinical trials of its Alzheimer’s and depression therapy candidate, Xanamem.